Viewing Study NCT06703892

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:56 PM
Ignite Modification Date: 2026-01-02 @ 12:32 PM
Study NCT ID: NCT06703892
Status: RECRUITING
Last Update Posted: 2025-12-22
First Post: 2024-11-20
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B Cell Lymphoma Relapsed View
None Diffuse Large B Cell Lymphoma Refractory View
None Follicular Lymphoma ( FL) View
None Primary Mediastinal Large B-Cell Lymphoma-Refractory View
None Primary Mediastinal Large B-Cell Lymphoma-Recurrent View
None High-grade B-cell Lymphoma (HGBCL) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CAR T View